Treatment Action Group

An Activist's Guide to the TB LAM Test

Treatment Action Group releases an updated version of its Activist’s Guide to the LAM Test with a complementary resource that tracks the status of LAM uptake in the 30 high TB/HIV burden countries.

Read More →

Good COPs or Bad COPs webinar: Promoting interventions for co-infections and AIDS in 2020 PEPFAR COPs - webinar materials now available online

Treatment Action Group, Médecins Sans Frontières and Health GAP conducted a webinar on 22 January 2020 on how to engage in PEPFAR Country Operational Plans (COPs) advocacy and promote the prioritization of interventions that address HIV co-infections and AIDS.

Read More →

Webinar: What’s New—and Next—for TB Vaccines

Treatment Action Group (TAG) and AVAC will host a webinar on 6 February 2020 featuring an update on recent vaccine results and possible next steps with M72/AS01E, one of several new TB vaccine candidates.

Read More →

Sanofi withdraws two patent applications on life-saving TB prevention drugs in Europe and in Indonesia

Activists urge Sanofi to do the same in other countries.

Read More →

Good COPs or Bad COPs webinar: Promoting interventions for co-infections and AIDS in 2020 PEPFAR COPs

Treatment Action Group, Médecins Sans Frontières and Health GAP will host a webinar on 22 January 2020 on how to engage in PEPFAR Country Operational Plans (COPs) advocacy and promote the prioritization of interventions that address HIV co-infections and AIDS.

Read More →

New TAG report: Funding for TB research climbed to new high in 2018

The report — Tuberculosis Research Funding Trends, 2005–2018 — presents new data on funding for TB research and development in 2018 and analyzes trends in spending since 2005.

Read More →

TAG applauds Indian TB activists in opposing patents for critical TB prevention drugs

Civil society takes legal action to contest patent applications filed by Sanofi on fixed-dose combinations of two decades-old drugs used to prevent TB.

Read More →

TAG’s 2019 Pipeline Report: Three TB sections released

The sections provide an overview of TB diagnostics, vaccines and treatment.

Read More →

Public investments in TB medicine bedaquiline far exceed those of developer Johnson & Johnson

Quantification of investments in the development of bedaquiline finds total public and philanthropic expenditures are three to five times those of Johnson & Johnson.

Read More →

Protestors demand Cepheid halve the price of GeneXpert TB tests to US$5

The high cost of GeneXpert tests for TB leaves open a critical gap in the diagnosis of TB and fails to consider volume of sales and public investments in the development of GeneXpert.

Read More →

Page 2 of 16 · Total posts: 10

←First 1 2 3 Last→